Eli Lilly announced a major acquisition to strengthen its presence in the growing sleep disorder treatment market. The pharmaceutical giant agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion. This move highlights rising global demand for innovative therapies targeting sleep disorder conditions and neurological health. The company will pay $38 per share in cash, offering a significant premium to Centessa shareholders. Additionally, investors may receive up to $9 per share through contingent value rights tied to regulatory milestones. As a result, the total deal value could reach $7.8 billion if key drug approvals materialize.
This acquisition marks Lilly’s largest deal since its 2019 purchase of Loxo Oncology. Moreover, it reflects a strategic shift toward diversifying beyond its successful metabolic and weight-loss drug portfolio. Therefore, the company aims to expand into neuroscience and sleep disorder therapeutics, which analysts consider a high-growth segment.
Centessa Pharmaceuticals, a clinical-stage biotechnology firm, focuses on developing treatments for sleep disorder conditions such as narcolepsy. Its lead drug candidate, cleminorexton, targets the orexin system, which regulates the human sleep-wake cycle. Notably, this mechanism plays a critical role in managing excessive daytime sleepiness and related sleep disorder symptoms.
Cleminorexton has shown promising results in mid-stage clinical trials for narcolepsy and idiopathic hypersomnia. Consequently, analysts believe the drug could become a best-in-class treatment if it gains regulatory approval. Furthermore, projections suggest the therapy could generate significant revenue in the coming decade, strengthening Lilly’s sleep disorder pipeline.
The sleep disorder market presents a substantial opportunity for pharmaceutical companies worldwide. According to health estimates, tens of millions of people suffer from sleep disorder conditions in the United States alone. Therefore, demand for effective therapies continues to rise as awareness and diagnosis improve. Lilly’s acquisition also reflects broader industry interest in sleep disorder innovation. In recent years, several drugmakers have invested heavily in orexin-based therapies targeting sleep-wake regulation. Consequently, competition is intensifying as companies seek to capture market share in this emerging therapeutic area.
In addition, the deal strengthens Lilly’s neuroscience portfolio, which already includes treatments for migraine and Alzheimer’s disease. By adding Centessa’s pipeline, the company enhances its ability to address complex brain-related conditions, including sleep disorders. This strategic alignment supports Lilly’s long-term growth objectives and research capabilities.
The agreement follows a series of recent acquisitions by Lilly aimed at expanding its drug development pipeline. Earlier this year, the company acquired multiple biotech firms to boost its capabilities in genetic medicine and autoimmune therapies. Therefore, the Centessa deal continues a pattern of aggressive investment in innovative healthcare solutions.
Market reaction to the announcement was immediate and significant. Centessa’s shares surged sharply following the news, reflecting investor confidence in the transaction. Meanwhile, Lilly’s stock also recorded gains, signaling positive sentiment toward its expansion into the sleep disorder sector. Analysts suggest the acquisition could trigger further consolidation in the sleep disorder drug market. Some experts believe other pharmaceutical companies may pursue similar deals to remain competitive. Consequently, the transaction may accelerate innovation and investment across the broader sleep disorder landscape.
The deal is expected to close in the third quarter of 2026, subject to regulatory approvals and customary conditions. Once completed, Lilly plans to integrate Centessa’s research programs into its existing operations. This integration will likely accelerate the development of new sleep disorder treatments and expand patient access to advanced therapies.
Overall, Lilly’s acquisition of Centessa represents a significant milestone in the evolution of sleep disorder medicine. As the company advances its pipeline, it aims to address unmet medical needs affecting millions of patients worldwide. Therefore, this strategic move positions Lilly as a key player in the future of sleep disorder treatment and neuroscience innovation.
